Oncology Central

Vinflunine for the treatment of metastatic transitional cell carcinoma: recent evidence from clinical trials and observational studies


The microtubule inhibitor vinflunine is currently the only cytotoxic drug approved in Europe for the treatment of patients with metastatic transitional cell carcinoma who failed first-line platinum-based chemotherapy. Indeed, the only Phase III trial ever conducted in this setting demonstrated a benefit in progression-free and overall survival for patients receiving vinflunine plus best supportive care compared with best supportive care alone.

To view restricted content, please:

Leave A Comment